REPATHA
Google image searchProduct monograph
Active ingredient
evolocumab, 140 MG/ML
DIN: 02446057
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: 1 ML SINGLE USE PREFILLED SYRINGE AND AUTOINJECTOR
Schedule: Prescription / Schedule D
Company: AMGEN CANADA INC
Date: 28-SEP-2015
ATC:
- C10 — LIPID MODIFYING AGENTS (ATC, ATC/DDD, )
- C10A — LIPID MODIFYING AGENTS, PLAIN (ATC, ATC/DDD)
- C10AX — Other lipid modifying agents (ATC, ATC/DDD)
- C10AX13 — EVOLOCUMAB (ATC/DDD)
Reference brand drug: Repatha
